No seroconversion in a retrospective study analyzing QuantiFERON TB ‐gold testing in pediatric psoriasis and hidradenitis suppurativa patients taking biologic therapy at an academic center in New York City
Pediatric Dermatology · 2024
DOI: 10.1111/pde.15577 ↗Kurz gefasst
Leserbrief in der Zeitschrift Pediatric Dermatology, 2024. Verfasst von Apostolos Katsiaunis und 2 weiteren Autor:innen. Beteiligte Einrichtung: Tufts University School of Medicine, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Psoriasis, Seroconversion. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
Guidelines are inconsistent regarding annual QuantiFERON® TB Gold (QFT) tests in children taking biologics for dermatological conditions, and there is limited research on seroconversion, especially in regions with high tuberculosis (TB) prevalence. A retrospective review of pediatric patients taking biologic treatment for psoriasis or hidradenitis suppurativa (HS) who had one baseline and at least one follow‐up QFT test was conducted to assess for seroconversion during treatment. Thirty‐two patients were included, with no instances of seroconversion. These findings suggest that routine annual TB rescreening for pediatric patients taking biologic therapy for dermatologic conditions may not be necessary without additional TB exposure risks or symptomatology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Tufts University School of Medicine, Boston, Massachusetts, USA.
- School of Medicine, New York Medical College, Valhalla, New York, USA.
- Department of Dermatology, Weill Cornell Medicine, New York, New York, USA.
ORCID-Profile: Apostolos Katsiaunis, Shari R Lipner
Zitieren
APA
Katsiaunis, A., Conway, J., & Lipner, S. R. (2024). No seroconversion in a retrospective study analyzing QuantiFERON TB ‐gold testing in pediatric psoriasis and hidradenitis suppurativa patients taking biologic therapy at an academic center in New York City. Pediatric Dermatology. https://doi.org/10.1111/pde.15577
Vancouver
Katsiaunis A, Conway J, Lipner SR. No seroconversion in a retrospective study analyzing QuantiFERON TB ‐gold testing in pediatric psoriasis and hidradenitis suppurativa patients taking biologic therapy at an academic center in New York City. Pediatric Dermatology. 2024. doi:10.1111/pde.15577
BibTeX
@article{Katsiaunis2024,
author = {Katsiaunis, Apostolos and Conway, Jade and Lipner, Shari R},
title = {No seroconversion in a retrospective study analyzing QuantiFERON TB ‐gold testing in pediatric psoriasis and hidradenitis suppurativa patients taking biologic therapy at an academic center in New York City},
journal = {Pediatric Dermatology},
year = {2024},
doi = {10.1111/pde.15577}
}
EUVIMED